Gallic acid impairs fructose-driven de novo lipogenesis and ameliorates hepatic steatosis via AMPK-dependent suppression of SREBP-1/ACC/FASN cascade.

[1]  Yung-chi Cheng,et al.  Gallic Acid Ameliorated Impaired Lipid Homeostasis in a Mouse Model of High-Fat Diet—and Streptozotocin-Induced NAFLD and Diabetes through Improvement of β-oxidation and Ketogenesis , 2021, Frontiers in Pharmacology.

[2]  Y. Zhang,et al.  Gallic acid: Pharmacological activities and molecular mechanisms involved in inflammation-related diseases. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[3]  K. Kondo,et al.  Gallic Acid Inhibits Lipid Accumulation via AMPK Pathway and Suppresses Apoptosis and Macrophage-Mediated Inflammation in Hepatocytes , 2020, Nutrients.

[4]  Qian Yang,et al.  Gastroprotective effect of gallic acid against ethanol-induced gastric ulcer in rats: Involvement of the Nrf2/HO-1 signaling and anti-apoptosis role. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[5]  S. Santos,et al.  Oral gallic acid improve liver steatosis and metabolism modulating hepatic lipogenic markers in obese mice , 2020, Experimental Gerontology.

[6]  A. Sanyal,et al.  MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. , 2020, Gastroenterology.

[7]  Zhenpeng Qiu,et al.  Ellagic acid ameliorates AKT-driven hepatic steatosis in mice by suppressing de novo lipogenesis via the AKT/SREBP-1/FASN pathway. , 2019, Food & function.

[8]  M. Farzaei,et al.  Pharmacological effects of gallic acid in health and diseases: A mechanistic review , 2019, Iranian journal of basic medical sciences.

[9]  Kil-Nam Kim,et al.  Palmitate induces nitric oxide production and inflammatory cytokine expression in zebrafish , 2018, Fish & shellfish immunology.

[10]  B. Neuschwander‐Tetri,et al.  Mechanisms of NAFLD development and therapeutic strategies , 2018, Nature Medicine.

[11]  Wenfeng Li,et al.  Hepatoprotective Effects of Sophoricoside against Fructose-Induced Liver Injury via Regulating Lipid Metabolism, Oxidation, and Inflammation in Mice. , 2018, Journal of food science.

[12]  Yang Wang,et al.  Gallic acid, a natural polyphenol, protects against tert-butyl hydroperoxide- induced hepatotoxicity by activating ERK-Nrf2-Keap1-mediated antioxidative response. , 2017, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[13]  J. de Bandt,et al.  Fructose and NAFLD: The Multifaceted Aspects of Fructose Metabolism , 2017, Nutrients.

[14]  Zhenpeng Qiu,et al.  Methylated urolithin A, the modified ellagitannin-derived metabolite, suppresses cell viability of DU145 human prostate cancer cells via targeting miR-21. , 2016, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[15]  G. Steinberg,et al.  Treatment of nonalcoholic fatty liver disease: role of AMPK. , 2016, American journal of physiology. Endocrinology and metabolism.

[16]  E. Tsochatzis,et al.  The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). , 2016, Metabolism: clinical and experimental.

[17]  Xingbin Yang,et al.  Enhancing the hepatic protective effect of genistein by oral administration with stachyose in mice with chronic high fructose diet consumption. , 2016, Food & function.

[18]  C. Kahn,et al.  Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease , 2016, Digestive Diseases and Sciences.

[19]  A. Minihane,et al.  Polyphenols and non-alcoholic fatty liver disease: impact and mechanisms , 2015, Proceedings of the Nutrition Society.

[20]  T. Auguet,et al.  Molecular pathways in non-alcoholic fatty liver disease , 2014, Clinical and experimental gastroenterology.

[21]  X. Qin,et al.  Gallic Acid Ameliorated Impaired Glucose and Lipid Homeostasis in High Fat Diet-Induced NAFLD Mice , 2014, PloS one.

[22]  J. Browning,et al.  Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. , 2014, Gastroenterology.

[23]  Rohit Loomba,et al.  The global NAFLD epidemic , 2013, Nature Reviews Gastroenterology &Hepatology.

[24]  D. Calvisi,et al.  Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. , 2011, Gastroenterology.

[25]  J. Schwarz,et al.  The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome , 2010, Nature Reviews Gastroenterology &Hepatology.

[26]  A. Chakraborti,et al.  Fructose-induced structural and functional modifications of hemoglobin: implication for oxidative stress in diabetes mellitus. , 2008, Biochimica et biophysica acta.

[27]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[28]  Khosrow Adeli,et al.  Fructose, insulin resistance, and metabolic dyslipidemia , 2005, Nutrition & metabolism.

[29]  M. Beylot,et al.  Role of human liver lipogenesis and reesterification in triglycerides secretion and in FFA reesterification. , 1998, American journal of physiology. Endocrinology and metabolism.

[30]  L. Henry,et al.  NAFLD AND NASH: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018 .

[31]  Shanhua Xu,et al.  Gallic acid regulates body weight and glucose homeostasis through AMPK activation. , 2015, Endocrinology.